How Spravato Works in the Brain, and Who It Helps
Zora Neuro Spa Editorial · October 4, 2026

Depression that hasn't responded to two or three medications can make you feel like you've run out of options. If you've been searching for Spravato treatment near me in Boise or Eagle, you've probably found plenty of clinic listings but very little plain-English explanation of what the drug actually does inside your brain, or who it's meant for. This guide covers the mechanism, the eligibility rules, the side effects, and how to vet a certified clinic.
Quick Answer
Spravato (esketamine) is an FDA-approved prescription nasal spray for adults with treatment-resistant depression. Unlike SSRIs, which act on serotonin, esketamine is an NMDA receptor antagonist — it works on the brain's glutamate system, the chemical pathway involved in learning and synaptic connection. Because of its sedation and dissociation risks, it can only be given in a clinic certified under a federal safety program, with about two hours of monitoring after each dose, per the FDA prescribing information.
TL;DR
- Spravato is esketamine, the S-form of ketamine, delivered as a self-administered nasal spray under direct medical supervision. See what the drug actually is
- It targets glutamate, not serotonin. The FDA label identifies it as a non-selective NMDA receptor antagonist and notes the precise mechanism of its antidepressant effect is not fully established. See how NMDA blockade is thought to work
- Eligibility is specific. It's labeled for adults with major depressive disorder who haven't responded to adequate trials of other antidepressants, and several medical conditions rule it out. Check the eligibility and disqualifier list
- Dissociation, dizziness, nausea and sedation are among the most commonly reported adverse reactions, which is why monitoring is mandatory. Review the side effects and monitoring protocol
- You can't get it just anywhere. Only certified treatment centers may dispense it. Use the clinic vetting checklist
In This Article
- What Is Spravato, Exactly?
- How Does Spravato Work in the Brain?
- How Well Does Spravato Work for Treatment-Resistant Depression?
- Who Qualifies for Spravato — and What Disqualifies You?
- What Are the Side Effects and How Are They Monitored?
- What Does the Treatment Schedule Look Like?
- How Do You Find Spravato Treatment Near Me?
- Spravato or IV Ketamine — Which Fits Your Situation?
What Is Spravato, Exactly?
Spravato is the brand name for esketamine nasal spray, a prescription medication used alongside an oral antidepressant in adults with depression that hasn't responded to other treatments. You spray it yourself, but only inside a certified clinic and only while a healthcare provider watches.
A few definitions make the rest of this easier:
- Esketamine is the S-enantiomer of ketamine — one of the two mirror-image forms of the ketamine molecule, isolated and purified for pharmaceutical use.
- An enantiomer is one of two molecules that share the same atoms but are arranged as mirror images, like a left and right hand. The two halves can behave differently in the body.
- REMS refers to a Risk Evaluation and Mitigation Strategy — an FDA-required safety program that restricts where and how a medication can be dispensed.
The FDA prescribing information describes esketamine nasal spray as supplied in devices delivering set doses, with 56 mg and 84 mg treatment doses used in the labeled regimens. Dosing is chosen and adjusted by the prescriber, not the patient.
⚠️ Important distinction: Spravato is not the same thing as the intravenous ketamine many clinics use off-label. They share a parent molecule, but they differ in delivery route, regulatory status, dosing control, and clinical setting. If you're weighing both, read our breakdown of Spravato vs IV ketamine in Boise & Eagle.
How Does Spravato Work in the Brain?
Esketamine acts on the glutamate system rather than the serotonin system. The FDA prescribing information describes esketamine as a non-selective, non-competitive antagonist of the NMDA receptor, and states that the mechanism behind its antidepressant effect is not fully established.
An NMDA receptor is a docking site on brain cells that responds to glutamate, the brain's main excitatory messenger. Glutamate is involved in learning, memory, and the formation of connections between neurons.
Here is the sequence researchers most commonly propose, presented as the leading hypothesis rather than settled fact:
- Receptor blockade. Esketamine blocks NMDA receptors, with particular effect on inhibitory interneurons — the cells that normally keep glutamate signaling in check.
- Glutamate release. With that brake eased, glutamate levels rise briefly in regions including the prefrontal cortex.
- AMPA activation. The extra glutamate stimulates a different receptor type, AMPA, shifting the pattern of signaling between neurons.
- Synaptic remodeling. Downstream growth-factor pathways are thought to encourage new or strengthened connections between neurons — a process related to neuroplasticity, which refers to the brain's capacity to reorganize its connections in response to experience and signaling.

The broader clinical pharmacology of the ketamine molecule — including its NMDA antagonism, dosing considerations and adverse effect profile — is summarized in the peer-reviewed StatPearls monograph on ketamine.
Key takeaway: Spravato is understood to act on glutamate signaling and synaptic connectivity, a different pathway than the monoamine systems most oral antidepressants target — though the FDA label is explicit that the antidepressant mechanism isn't fully pinned down.
Why Is Spravato's Mechanism Different From an SSRI?
SSRIs work further downstream. They increase the availability of serotonin in the synapse, and the therapeutic effect is generally attributed to gradual adaptations in receptor sensitivity and signaling that follow. The National Institute of Mental Health notes that antidepressant medications commonly require a period of weeks before a full effect is assessed.
Esketamine enters the system at a different point entirely, acting directly on glutamate receptors. That difference in target is the reason it's considered an option when multiple serotonin- or norepinephrine-based medications haven't worked.
What that means for any individual still has to be determined clinically. Response varies between people, and no mechanism explanation predicts whether a specific patient will benefit.
How Well Does Spravato Work for Treatment-Resistant Depression?
Treatment-resistant depression (TRD) refers to major depressive disorder that has not responded adequately to at least two different antidepressants, each taken at a sufficient dose for a sufficient length of time. That definition is the gateway to the Spravato label.
The FDA approved esketamine nasal spray for use with an oral antidepressant in adults with treatment-resistant depression, and the clinical trial designs and results that supported that decision are summarized in the prescribing information. Rather than reproduce trial figures secondhand, we'd point you to that document — it's the primary source, and your prescriber can walk you through what the data means for your situation.
A few honest framing points:
- Trial averages describe groups, not individuals. Some participants respond; some do not.
- Spravato is studied and labeled as an addition to an oral antidepressant in the TRD indication, not simply as a swap.
- Suitability, dose, and continuation are clinical decisions made with a prescriber after a full history review.
| Factor | Spravato (esketamine) | IV ketamine | Oral antidepressant augmentation |
|---|---|---|---|
| FDA status for depression | Approved under a restricted program | Used off-label for psychiatric indications | Varies by agent; several are approved |
| Setting | Certified clinic, supervised dosing | Clinic or infusion suite, supervised | Home, self-administered |
| Route | Nasal spray | Intravenous infusion | Oral tablet or capsule |
| Monitoring required | Yes — post-dose observation period | Yes — during and after infusion | Routine office follow-up |
| Insurance handling | Commonly billed with prior authorization | Often self-pay | Typically covered as pharmacy benefit |
Treasure Valley readers comparing options locally may also want our overview of esketamine for treatment-resistant depression in Boise.
Who Qualifies for Spravato — and What Disqualifies You?
Eligibility starts with two things: an adult diagnosis of major depressive disorder, and a documented history of inadequate response to prior antidepressant treatment. The FDA label defines the indications, contraindications and warnings in full.
Likely to be considered a candidate if you:
- Are 18 or older with a confirmed major depressive disorder diagnosis
- Have tried at least two antidepressants at adequate dose and duration without adequate response
- Can attend a clinic repeatedly on a set schedule
- Can arrange a ride home after every session
- Have blood pressure that is controlled and monitored
Factors that can rule you out or require careful screening, per the label's contraindications and warnings:
- Aneurysmal vascular disease, including of the brain, chest or abdomen
- Arteriovenous malformation
- A history of intracerebral hemorrhage
- Known hypersensitivity to esketamine, ketamine, or any component of the spray
- Pregnancy — the label addresses use in pregnancy and lactation
- Blood pressure or cardiovascular status that isn't stable
- Psychosis, or bipolar disorder that isn't stable, which calls for careful psychiatric evaluation
- Substance use concerns, given the label's abuse and misuse warning
- No reliable transportation home after dosing

Bring this list to your consultation. Documentation of your prior medication trials — names, doses, dates, duration — is also what insurers typically want to see, and we've covered how insurance and prior authorization work for Spravato in Idaho separately.
Key takeaway: The most common reason people are turned away isn't clinical — it's missing documentation of prior antidepressant trials. Gather those records before your first appointment.
What Are the Side Effects and How Are They Monitored?
Dissociation, dizziness, nausea, sedation, vertigo and transient increases in blood pressure are among the adverse reactions listed most prominently in the FDA prescribing information. The monitoring period after dosing exists specifically because of them.
Dissociation refers to a temporary sense of detachment from your body, surroundings, or the passage of time. It's an expected, documented effect of this medication class rather than a sign something has gone wrong — and it's one reason a provider stays with you.
| Effect category | Examples from the label | When it's handled |
|---|---|---|
| Common, expected | Dissociation, dizziness, nausea, sedation, vertigo, altered taste | During the in-clinic observation period |
| Cardiovascular | Increased blood pressure | Checked before dosing, after dosing, and before discharge |
| Serious warnings | Sedation, dissociation, abuse and misuse potential, suicidal thoughts and behaviors | Addressed by the Boxed Warning and the restricted dispensing program |
Spravato carries a Boxed Warning — the FDA's most serious warning category — covering sedation, dissociation, the potential for abuse and misuse, and suicidal thoughts and behaviors. That warning is also why the medication is only available through a certified program with required post-dose monitoring.
Practically, a session includes a blood pressure reading before you dose, a recheck roughly 40 minutes after, and further checks until you're cleared to leave, as directed by the label. You stay at the clinic for the full observation period regardless of how you feel at minute 30.
For a deeper walkthrough, see a closer look at esketamine benefits and side effects.
⚠️ Tell your prescriber about every medication you take, including blood pressure drugs, stimulants, sedatives and anything that affects the central nervous system. Interactions matter here.
What Does the Treatment Schedule Look Like?
The labeled regimen is structured in phases. According to the FDA prescribing information, the induction phase involves twice-weekly dosing across the first four weeks, followed by a maintenance phase where dosing moves to once weekly and then, based on clinical judgment, to once weekly or once every two weeks.
Plan for roughly two to two and a half hours door to door per visit. The spray itself takes minutes; the observation period is the long part.

Before-and-after rules that the label specifies:
- No food for 2 hours before dosing
- No liquids for 30 minutes before dosing
- No driving until the next day, after a full night of restful sleep
- Arrange transportation home for every single session — this is not optional
- Nasal corticosteroid or decongestant users should ask about timing relative to dosing
Most people clear their calendar for the rest of the day after a session. Treat it like a procedure day, not an errand.
For a minute-by-minute picture of a single appointment, read what happens in a Spravato session, hour by hour.
How Do You Find Spravato Treatment Near Me?
Spravato can only be dispensed and administered at a certified treatment center under its restricted program, so searching for Spravato treatment near me is really a search for certified, supervised psychiatric care within driving distance. In the Treasure Valley, that generally means a clinic in Eagle, Boise or Meridian.
Use this six-point checklist when you call:
- Certification — Is the clinic certified to dispense esketamine under the required REMS program? Ask directly.
- Supervision — Will a qualified provider be on site for the entire observation period, not just at check-in?
- Monitoring protocol — How do they handle blood pressure checks, and what's the plan if a reading comes back elevated?
- Psychiatric continuity — Who manages your oral antidepressant and overall treatment plan alongside the spray?
- Insurance support — Will they handle prior authorization and appeals, and what documentation do they need from you?
- Transportation policy — What happens if your ride falls through? Some clinics will not dose you without a confirmed plan.
Two more things worth asking about: whether integration or talk-therapy support is available alongside dosing, and what the clinic does if you don't respond after the induction phase.
If you're comparing providers more broadly, our guide on how to find ketamine therapists near you covers vetting questions that apply to any supervised treatment. You can also start with a depression treatment consultation in Boise and Eagle to review your history and determine whether you meet the labeled criteria before committing to a schedule.
Spravato or IV Ketamine — Which Fits Your Situation?
Spravato tends to be the practical choice when the diagnosis matches the FDA-labeled indication and insurance coverage is a priority. IV ketamine is more often considered for conditions outside that label, including chronic pain, or when precise dose control during administration matters.
| Consideration | Spravato (esketamine) | IV ketamine |
|---|---|---|
| FDA approval for depression | Yes, under a restricted program | No — used off-label |
| Insurance likelihood | Often billable with prior authorization | Commonly self-pay |
| Delivery | Nasal spray, self-administered under supervision | Infusion administered by a clinician |
| Dose adjustment during session | Fixed dose strengths per the label | Infusion rate can be adjusted clinically |
| Conditions typically addressed | Labeled depression indications | Depression plus off-label pain indications |
| Required observation | Mandated post-dose monitoring period | Clinic-determined monitoring |
Neither option is universally better. The right one depends on your diagnosis, your medical history, your coverage, and how you tolerate each route.
Key takeaway: Let the diagnosis and your insurance situation drive the decision, not the delivery method. A full comparison lives in our guide to Spravato vs IV ketamine in Boise & Eagle.
Summary
Spravato is esketamine, an NMDA receptor antagonist delivered as a supervised nasal spray for adults whose depression hasn't responded to other antidepressants. It works on the glutamate system rather than serotonin, which is why it's positioned as an option after standard medications fall short. Eligibility hinges on documented prior treatment trials and the absence of specific vascular and cardiovascular contraindications, and every dose requires in-clinic monitoring plus a ride home. If you're looking for Spravato treatment near me in the Boise or Eagle area, start by confirming a clinic's certification, then bring your medication history to a consultation. Results vary between individuals, and suitability is always decided clinically.
Frequently Asked Questions
How hard is it to get prescribed Spravato?
If you genuinely meet the labeled criteria, the clinical side is usually straightforward. The real hurdle is documentation — you need records showing two or more antidepressant trials at adequate dose and duration, plus prior authorization from your insurer. Many initial denials come down to incomplete paperwork rather than a clinical disagreement. Gathering pharmacy records and past prescriber notes ahead of your consultation speeds everything up.
Can you drive after a Spravato session?
No. The FDA prescribing information directs patients not to drive or operate machinery until the next day, after a full night of restful sleep. You must arrange transportation home from every session, and clinics certified under the required safety program will not dose you without a confirmed ride. Plan for a low-demand rest of the day.
Does Spravato work for anxiety or PTSD?
Spravato's FDA-labeled indications are depression-related, not anxiety or PTSD. Some people with depression also live with anxiety symptoms, and clinicians track those alongside mood during treatment, but anxiety and PTSD are not approved indications for this medication. If anxiety is your primary concern, an anxiety treatment consultation is a more appropriate starting point.
How long does relief from Spravato last?
Duration varies between individuals, and the labeled regimen accounts for that by moving from twice-weekly induction dosing to a maintenance phase of weekly or every-other-week dosing based on clinical judgment. Your prescriber reassesses at intervals and adjusts the schedule accordingly. There is no fixed answer that applies to everyone, which is why ongoing follow-up is built into the protocol.
Is Spravato the same as recreational ketamine?
No. Spravato is a purified, precisely dosed pharmaceutical administered under medical supervision with blood pressure monitoring and a required observation period. Unregulated ketamine obtained outside a clinic has unknown purity, unknown dose, and no monitoring. The FDA label includes a Boxed Warning covering abuse and misuse potential, which is precisely why dispensing is restricted to certified settings.
Information about third-party platforms reflects publicly available details at the time of writing and may have changed. Please verify directly with the provider. See our Terms of Use for more.